KRAS and non-small cell lung carcinoma: Other strategies under evaluation for KRAS mutant NSCLC include the inhibition of downstream signaling pathways with MEK inhibitors (NCT04967079, NCT03170206), either as monotherapy or combined with other molecules (NCT03170206, NCT04735068).